Literature DB >> 4212173

Modification of some of the toxic effects of daunomycin (NSC-82,151) by pretreatment with the antineoplastic agent ICRF 159 (NSC-129,943).

E H Herman, R M Mhatre, D P Chadwick.   

Abstract

Entities:  

Mesh：

Substances：

Year:  1974        PMID： 4212173     DOI： 10.1016/0041-008x(74)90031-3

Source DB:  PubMed          Journal:  Toxicol Appl Pharmacol        ISSN： 0041-008X            Impact factor:   4.219


× No keyword cloud information.
  9 in total

1.  Phase I study of doxorubicin, ICRF-187 and granulocyte/macrophage-colony-stimulating factor.

Authors:  C Walsh; R H Blum; R Oratz; A Goldenberg; A Downey; J L Speyer
Journal:  J Cancer Res Clin Oncol       Date:  1992       Impact factor: 4.553

2.  Phase I clinical trial and pharmacokinetics of weekly ICRF-187 (NSC 169780) infusion in patients with solid tumors.

Authors:  C L Vogel; E Gorowski; E Davila; M Eisenberger; J Kosinski; R P Agarwal; N Savaraj
Journal:  Invest New Drugs       Date:  1987       Impact factor: 3.850

Review 3.  Chemoprotectants: a review of their clinical pharmacology and therapeutic efficacy.

Authors:  M Links; C Lewis
Journal:  Drugs       Date:  1999-03       Impact factor: 9.546

4.  Reduction of chronic doxorubicin cardiotoxicity in beagle dogs by bis-morpholinomethyl derivative of razoxane (ICRF-159).

Authors:  E H Herman; V J Ferrans; H B Bhat; D T Witiak
Journal:  Cancer Chemother Pharmacol       Date:  1987       Impact factor: 3.333

Review 5.  A review of the use of chemoprotectants in cancer chemotherapy.

Authors:  C Lewis
Journal:  Drug Saf       Date:  1994-09       Impact factor: 5.606

6.  Metal binding by pharmaceuticals. Part 2. Interactions of Ca(II), Cu(II), Fe(II), Mg(II), Mn(II) and Zn(II) with the intracellular hydrolysis products of the antitumour agent ICRF 159 and its inactive homologue ICRF 192.

Authors:  Z X Huang; P M May; K M Quinlan; D R Williams; A M Creighton
Journal:  Agents Actions       Date:  1982-10

Review 7.  Oxidative stress, redox signaling, and metal chelation in anthracycline cardiotoxicity and pharmacological cardioprotection.

Authors:  Martin Stěrba; Olga Popelová; Anna Vávrová; Eduard Jirkovský; Petra Kovaříková; Vladimír Geršl; Tomáš Simůnek
Journal:  Antioxid Redox Signal       Date:  2012-10-12       Impact factor: 8.401

8.  Reduction of daunomycin toxicity by razoxane.

Authors:  G Wang; M D Finch; D Trevan; K Hellmann
Journal:  Br J Cancer       Date:  1981-06       Impact factor: 7.640

Review 9.  Dexrazoxane for the treatment of chemotherapy-related side effects.

Authors:  Seppo W Langer
Journal:  Cancer Manag Res       Date:  2014-09-15       Impact factor: 3.989
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.